Walgreens Boots Alliance Inc. (WBA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Walgreens: Acquisition Is The Best-Case Scenario For The Company
Walgreens Boots Alliance faces significant challenges, including rising inflation, heavy competition, and decreasing profitability, making it a Hold if the acquisition by Sycamore goes through. The company's financial health is concerning, with declining net income, negative free cash flow, and high debt levels, increasing the vulnerability to financial downturns. WBA's lack of its own Pharmacy Benefit Manager (PBM) puts it at a disadvantage compared to CVS, which owns Caremark and can better manage drug prices.
Walgreens Comeback? Private Equity Circling for a Buyout
Sometimes, the stock market gives investors the opportunity to play in the corporate leagues, where deals are made not on the stock chart or tape but at the negotiating table when markets are closed and everyone goes home. Today, a potential buyout deal is being discussed by a private equity firm looking to eat up and potentially turn around one of America's darlings in the retail sector, though one that has recently become a sort of “fallen angel,” so to speak.
Walgreens Boots Alliance: Last Change To Buy
Walgreens Boots Alliance faces significant challenges, including declining margins, rising labor costs, and fierce competition from online pharmacies and retail giants like Amazon and Walmart. The proposed $11.45 per share acquisition by Sycamore Partners, with an additional potential $3 per share, offers a 37% premium over the current share price. Despite a 4.1% revenue increase, profits remain elusive due to substantial write-downs and weaker sales of high-margin non-prescription items.
Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down
WBA delivers better-than-expected earnings and revenues in the second quarter of fiscal 2025.
WBA stock price: Walgreens beats on revenue in one of its last earnings reports as a public company
Shares in Walgreens Boots Alliance (Nasdaq: WBA) are trading slightly higher this morning after the company reported its Q2 2025 earnings. The results, which beat on earnings and revenue, are notable as they will be one of the last earnings reports the company posts as a publicly traded company.
Walgreens Continues Turnaround Efforts Ahead of Planned Acquisition by Private Equity Firm
Walgreens Boots Alliance (WBA) saw its second-quarter fiscal 2025 sales increase and its operating loss drop as it continues its turnaround plan and prepares to be acquired. The retail pharmacy company said in a Tuesday (April 8) earnings release that during the quarter ended Feb. 28, its sales rose 4.
Walgreens (WBA) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Walgreens (WBA) give insight into how the company performed in the quarter ended February 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Walgreens Boots Alliance (WBA) Beats Q2 Earnings and Revenue Estimates
Walgreens Boots Alliance (WBA) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $1.20 per share a year ago.
Walgreens tops estimates as drugstore chain cuts costs, prepares to go private
Walgreens reported fiscal second-quarter earnings and revenue that topped expectations, as the retail drugstore giant prepares to go private. In this article WBA
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Walgreens Settles Allegations of Submitting Inflated Prices to Medicaid Programs
Walgreens has agreed to pay $2.8 million to settle allegations that it submitted inflated prices to the Massachusetts and Georgia Medicaid programs for generic medications.
Walgreens to pay more than $2.85 million to settle US overbilling charges
Walgreens will pay more than $2.85 million to settle whistleblower allegations that the pharmacy overbilled Medicaid programs in Georgia and Massachusetts for generic medications, the U.S. Department of Justice said on Thursday.
